Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Serum osteoprotegerin levels and mammographic density among high-risk women.

Moran O, Zaman T, Eisen A, Demsky R, Blackmore K, Knight JA, Elser C, Ginsburg O, Zbuk K, Yaffe M, Narod SA, Salmena L, Kotsopoulos J.

Cancer Causes Control. 2018 Jun;29(6):507-517. doi: 10.1007/s10552-018-1035-y. Epub 2018 Apr 20.

PMID:
29679262
2.

SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML.

Dzneladze I, Woolley JF, Rossell C, Han Y, Rashid A, Jain M, Reimand J, Minden MD, Salmena L.

PLoS One. 2018 Feb 7;13(2):e0191510. doi: 10.1371/journal.pone.0191510. eCollection 2018. Erratum in: PLoS One. 2018 Mar 29;13(3):e0195417.

3.

microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.

Gabra MM, Salmena L.

Front Oncol. 2017 Oct 30;7:255. doi: 10.3389/fonc.2017.00255. eCollection 2017. Review.

4.

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Odén L, Akbari M, Zaman T, Singer CF, Sun P, Narod SA, Salmena L, Kotsopoulos J.

Oncotarget. 2016 Dec 27;7(52):86687-86694. doi: 10.18632/oncotarget.13417.

5.

Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.

Chehade R, Pettapiece-Phillips R, Salmena L, Kotlyar M, Jurisica I, Narod SA, Akbari MR, Kotsopoulos J.

Breast Cancer Res. 2016 Aug 17;18(1):87. doi: 10.1186/s13058-016-0739-8.

6.

Preface.

Salmena L, Stambolic V.

Methods Mol Biol. 2016;1388:v. No abstract available.

PMID:
27482589
7.

Measurement of PTEN by Flow Cytometry.

Woolley JF, Salmena L.

Methods Mol Biol. 2016;1388:39-51. doi: 10.1007/978-1-4939-3299-3_4.

PMID:
27033069
8.

PTEN: History of a Tumor Suppressor.

Salmena L.

Methods Mol Biol. 2016;1388:3-11. doi: 10.1007/978-1-4939-3299-3_1.

PMID:
27033066
9.

Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression.

Pettapiece-Phillips R, Kotlyar M, Chehade R, Salmena L, Narod SA, Akbari M, Jurisica I, Kotsopoulos J.

Cancer Prev Res (Phila). 2016 Jan;9(1):83-8. doi: 10.1158/1940-6207.CAPR-15-0291. Epub 2015 Nov 2.

10.

Targeting mitochondrial RNA polymerase in acute myeloid leukemia.

Bralha FN, Liyanage SU, Hurren R, Wang X, Son MH, Fung TA, Chingcuanco FB, Tung AY, Andreazza AC, Psarianos P, Schimmer AD, Salmena L, Laposa RR.

Oncotarget. 2015 Nov 10;6(35):37216-28. doi: 10.18632/oncotarget.6129.

11.

Phosphoinositide signaling in cancer: INPP4B Akt(s) out.

Woolley JF, Dzneladze I, Salmena L.

Trends Mol Med. 2015 Sep;21(9):530-2. doi: 10.1016/j.molmed.2015.06.006. Epub 2015 Jul 3.

PMID:
26150301
12.

In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.

Li Chew C, Lunardi A, Gulluni F, Ruan DT, Chen M, Salmena L, Nishino M, Papa A, Ng C, Fung J, Clohessy JG, Sasaki J, Sasaki T, Bronson RT, Hirsch E, Pandolfi PP.

Cancer Discov. 2015 Jul;5(7):740-51. doi: 10.1158/2159-8290.CD-14-1347. Epub 2015 Apr 16.

13.

Pseudogene redux with new biological significance.

Salmena L.

Methods Mol Biol. 2014;1167:3-13. doi: 10.1007/978-1-4939-0835-6_1. Review.

PMID:
24823767
14.

Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function.

Papa A, Wan L, Bonora M, Salmena L, Song MS, Hobbs RM, Lunardi A, Webster K, Ng C, Newton RH, Knoblauch N, Guarnerio J, Ito K, Turka LA, Beck AH, Pinton P, Bronson RT, Wei W, Pandolfi PP.

Cell. 2014 Apr 24;157(3):595-610. doi: 10.1016/j.cell.2014.03.027.

15.

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP.

Nat Genet. 2013 Jul;45(7):747-55. doi: 10.1038/ng.2650. Epub 2013 Jun 2.

16.

From photomorphogenesis to cancer: a CSN journey.

Salmena L, Hakem R.

Cell Cycle. 2013 Jan 15;12(2):205-6. doi: 10.4161/cc.23422. Epub 2012 Jan 15. No abstract available.

17.

The functions and regulation of the PTEN tumour suppressor.

Song MS, Salmena L, Pandolfi PP.

Nat Rev Mol Cell Biol. 2012 Apr 4;13(5):283-96. doi: 10.1038/nrm3330. Review.

PMID:
22473468
18.

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, Ghadirian P, Neuhausen SL, Demsky R, Tung N, Ainsworth P, Senter L, Eisen A, Eng C, Singer C, Ginsburg O, Blum J, Huzarski T, Poll A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res. 2012 Mar 9;14(2):R42.

19.

BRCA1 haploinsufficiency: consequences for breast cancer.

Salmena L, Narod S.

Womens Health (Lond). 2012 Mar;8(2):127-9. doi: 10.2217/whe.12.2.

PMID:
22375716
20.

BRCA1 and BRCA2 mutations and breast cancer.

Narod SA, Salmena L.

Discov Med. 2011 Nov;12(66):445-53.

Supplemental Content

Loading ...
Support Center